Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/13959
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | Gabriele, Joseph | en_US |
dc.contributor.advisor | Mishra, Ram | en_US |
dc.contributor.advisor | Doering, Laurie | en_US |
dc.contributor.author | Lubarda, Jovana | en_US |
dc.date.accessioned | 2014-06-18T17:05:42Z | - |
dc.date.available | 2014-06-18T17:05:42Z | - |
dc.date.created | 2014-02-04 | en_US |
dc.date.issued | 2014-04 | en_US |
dc.identifier.other | opendissertations/8791 | en_US |
dc.identifier.other | 9858 | en_US |
dc.identifier.other | 5060668 | en_US |
dc.identifier.uri | http://hdl.handle.net/11375/13959 | - |
dc.description.abstract | <p>Parkinson’s disease (PD) is a complex neurodegenerative movement disorder involving protein misfolding, mitochondrial dysfunction, and oxidative stress. The current dissertation, motivated by a lack of valid biomarkers and sustainable therapies, examined the potential application of a novel target for therapeutics and diagnostics of PD — the multifunctional, heat-shock like protein Catecholamine-Regulated Protein 40 (CRP40). The goal of this program of research was to elucidate further the implications of CRP40 in PD using a variety of molecular biology, bioinformatics, and clinical approaches through integrative collaborations with academia, government, and industry partners to translate scientific findings into real world solutions. Chapters 2 and 3 explored the potential therapeutic use and structure-function relationships of CRP40 through elucidating the smallest functional piece of this protein that was six times smaller, and validating a negative control for these experiments (Heat-Shock Protein 47). These initiatives could eventually lead to a small drug that could cross the blood-brain barrier and be targeted to the specific brain regions affected in PD. Chapter 4 examined the potential mechanisms of CRP40, and suggested that this protein may protect neurons from oxidative stress, maintain energy levels, and mitochondrial homeostasis, with important future implications for a variety of disorders. Finally, Chapter 5 presented compelling evidence for the potential use of CRP40 as a valid biomarker for early detection of PD and monitoring of disease progression. Overall, findings suggest that CRP40 may be a critical target for future breakthroughs in the diagnosis and treatment of PD.</p> | en_US |
dc.subject | Catecholamine-regulated protein 40 | en_US |
dc.subject | Parkinson’s disease | en_US |
dc.subject | movement disorder | en_US |
dc.subject | protein cloning | en_US |
dc.subject | oxidative stress | en_US |
dc.subject | Diagnosis | en_US |
dc.subject | Medical Biochemistry | en_US |
dc.subject | Medical Molecular Biology | en_US |
dc.subject | Nervous System Diseases | en_US |
dc.subject | Therapeutics | en_US |
dc.subject | Diagnosis | en_US |
dc.title | CATECHOLAMINE-REGULATED PROTEIN 40 IN PARKINSON’S DISEASE | en_US |
dc.type | thesis | en_US |
dc.contributor.department | Neuroscience | en_US |
dc.description.degree | Doctor of Science (PhD) | en_US |
Appears in Collections: | Open Access Dissertations and Theses |
Files in This Item:
File | Size | Format | |
---|---|---|---|
fulltext.pdf | 25.74 MB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.